Expertise in
30
conditions

Dr. Maciej Mrugala

Neurology | Oncology
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
30
conditions
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maciej Mrugala is a Neurologist and an Oncologist in Scottsdale, Arizona. Dr. Mrugala is highly rated in 30 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 90 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Sanford Health
  • HMO
  • PPO

Locations

MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259

Additional Areas of Focus

Dr. Mrugala has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU
Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU
Enrollment Status: Recruiting
Publish Date: April 06, 2025
Intervention Type: Procedure, Drug
Study Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU
Study Phase: Phase 1
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2023
View 5 Less Clinical Trials

90 Total Publications

Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Journal: Neuro-oncology advances
Published: December 30, 2024
Similar Doctors
Expertise in
24
conditions
Dr. Charles H. Adler
Neurology
Expertise in
24
conditions
Dr. Charles H. Adler
Neurology

Mayo Clinic Arizona

5701 E Mayo Blvd, 
Phoenix, AZ 
 (10.7 mi)
480-342-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Adler is a Neurologist in Phoenix, Arizona. Dr. Adler is highly rated in 24 conditions, according to our data. His top areas of expertise are Movement Disorders, Parkinson's Disease, Lewy Body Dementia (LBD), Tissue Biopsy, and Deep Brain Stimulation. Dr. Adler is currently accepting new patients.

Expertise in
14
conditions
Dr. Amir Azadi
Oncology | Hematology | Hematology Oncology
Expertise in
14
conditions
Dr. Amir Azadi
Oncology | Hematology | Hematology Oncology

Honorhealth Ambulatory

19646 N 27th Ave, Suite 301, 
Phoenix, AZ 
 (19.4 mi)
855-485-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amir Azadi is an Oncologist and a Hematologist in Phoenix, Arizona. Dr. Azadi is highly rated in 14 conditions, according to our data. His top areas of expertise are Gliosarcoma, Glioblastoma, Astrocytoma, and Embryonal Tumor with Multilayered Rosettes.

Expertise in
25
conditions
Dr. Alyx Porter
Neurology | Hematology | Oncology
Expertise in
25
conditions
Dr. Alyx Porter
Neurology | Hematology | Oncology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (10.7 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alyx Porter is a Neurologist and a Hematologist in Phoenix, Arizona. Dr. Porter is highly rated in 25 conditions, according to our data. Her top areas of expertise are Gliomatosis Cerebri, Radiation Induced Meningioma, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mrugala's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 12 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile